At Quotient Sciences, we will support your small molecule throughout its entire journey from drug discovery to drug development through to drug product supply.
For over 30 years, we have accelerated small molecule drug development and manufacturing to provide leading solutions for our pharmaceutical and biotechnology customers.
The major challenges faced today at our pharmaceutical industry partners are working with small molecules that have poor solubility and bioavailability. At Quotient Sciences, we aim to solve these before the clinical stage, this ensures the viability of compounds and initiates the formulation process. Other challenges our partners face, that we help with, include target identification, target validation, lead optimization, and toxicity. Working together, we can overcome the complex scientific challenges to ensure that we maximise the opportunities and value of small molecule drugs in development.
Our commitment and culture provide all our partners with a simple, agile and collaborative way of working. We prioritise efficiency, quality and speed of delivery, putting your drug product first.
At Quotient Sciences we recognise that many small molecule candidates in the pipeline today are more complex than ever before and present more challenges that we must overcome as an industry leader.
Wherever possible, we harness new technologies that complement our existing capabilities, while maximising value for our customers. As all leading pharmaceutical and biotechnology companies increasingly look to emerging technologies in their API, we constantly review and endeavour to evaluate those new technologies and increase our specialised expertise via our state-of-the-art facilities.
We will always look to accelerate our delivery timelines, cutting through silos to maximise the value we offer to our customers with the help of our flagship, integrated Translational Pharmaceutics® drug delivery platform.